Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q06330
UPID:
SUH_HUMAN
Alternative names:
CBF-1; J kappa-recombination signal-binding protein; RBP-J kappa; Renal carcinoma antigen NY-REN-30
Alternative UPACC:
Q06330; B4DY22; Q5XKH9; Q6P1N3
Background:
The Recombining binding protein suppressor of hairless, known by alternative names such as CBF-1, RBP-J kappa, plays a pivotal role in Notch signaling. This pathway is crucial for cell-cell communication, influencing a wide range of cell fate decisions. It functions as a transcriptional repressor or activator, depending on its association with Notch proteins, and is involved in various cellular processes including DNA binding and hypoxia response.
Therapeutic significance:
Linked to Adams-Oliver syndrome 3, a genetic condition marked by skin and limb abnormalities, understanding the role of this protein could open doors to potential therapeutic strategies. Its involvement in Notch signaling pathways offers a promising target for addressing the syndrome's manifestations.